Australia markets closed

Nuvation Bio Inc. (NUVB)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
3.6400-0.3300 (-8.31%)
At close: 04:00PM EDT
3.6900 +0.05 (+1.37%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.9700
Open4.0300
Bid3.6000 x 1000
Ask3.6400 x 1000
Day's range3.5700 - 4.1598
52-week range0.9500 - 4.1598
Volume5,327,292
Avg. volume1,071,840
Market cap797.327M
Beta (5Y monthly)1.19
PE ratio (TTM)N/A
EPS (TTM)-0.3500
Earnings date02 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.70
  • Business Wire

    Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

    NEW YORK, March 28, 2024--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company’s commercial strategy and operations, including marketing, sales, and market access.

  • Business Wire

    Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

    NEW YORK, March 25, 2024--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, and AnHeart Therapeutics Ltd. (AnHeart), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced that the companies have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction (the

  • Business Wire

    Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

    NEW YORK, March 14, 2024--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the first patient has been dosed in a Phase 1/2 study of NUV-1511, the Company’s first DDC to enter the clinic.